A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes

Clinical Breast Cancer

Volumn 7, Issue 5, 2006, Pages 401-405

  Kellokumpu Lehtinen, Pirkko Liisa ^a,b   Sunela, Kaisa ^a   Lehtinen, Ilari ^b   Joensuu, Heikki ^c   Sjöström Mattson, Johanna ^c  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Combination therapy; Hand foot syndrome; Oral fluoropyrimidines

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPECITABINE; DIURETIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; HORMONE; NAVELBINE; PERTUZUMAB; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HAND FOOT SYNDROME; HEART DISEASE; HEART FAILURE; HUMAN; INFECTION; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAXIMUM TOLERATED DOSE; METASTASIS POTENTIAL; MOTONEURON; MOTOR DYSFUNCTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHY; NEUTROPENIA; OPTIMAL DRUG DOSE; PHASE 1 CLINICAL TRIAL; PLEURA METASTASIS; RECOMMENDED DRUG DOSE; SENSORY DYSFUNCTION; SIDE EFFECT; SOFT TISSUE METASTASIS; SOMATOSENSORY CORTEX; THROMBOCYTOPENIA; VOMITING;

EID: 33846516907     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2006.n.057     Document Type: Article

References (31)

1. Joensuu H, Holli K, Heikkinen M, et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 1998; 16:3720-3730.
2. Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer 2000; 1:32-40.
3. Dieras V, Extra JM, Bellissant E, et al. Efficacy and tolerance of vinorelbine and fluorouracil combination as first-line chemotherapy of advanced breast cancer: results of a phase II study using a sequential group method. J Clin Oncol 1996; 14:3097-3104.
4. Nole F, de Braud F, Aapro M, et al. Phase I-II study of vinorelbine in combination with 5-fluorouracil and folinic acid as first-line chemotherapy in metastatic breast cancer: a regimen with a low subjective toxic burden. Ann Oncol 1997; 8:865-870.
5. Berruti A, Sperone P, Bottini A, et al. Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines. J Clin Oncol 2000; 18:3370-3377.
6. Bonneterre J, Roche H, Monnier A, et al. Docetaxel vs 5-fluorouracil plus vinorelbine in metastatic breast cancer after anthracycline therapy failure. Br J Cancer 2002; 87:1210-1215.
7. Pienkowski T, Jagiello-Gruszfeld A. Five-day infusion of fluorouracil and vinorelbine for advanced breast cancer patients treated previously with anthracyclines. Int J Clin Pharmacol Res 2001; 21:111-117.
8. Zambetti M, Mariani G, Demicheli R, et al. Five-day infusion fluorouracil plus vinorelbine in women with breast cancer previously treated with anthracyclines and paclitaxel. Breast Cancer Res Treat 2000; 62:135-139.
9. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998; 34:1274-1281.
10. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17:485-493.
11. Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92:1759-1768.
12. Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004; 40:536-542.
13. )) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003; 14:1227-1233.
14. Talbot DC, Moiseyenko V, Van Belle S, et al. Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. Br J Cancer 2002; 86:1367-1372.
15. Oshaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12:1247-1254.
16. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxal combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-2823.
17. Ahn JH, Kim SB, Kim TW, et al. Capecitabine and vinorelbine in patients with metastatic breast cancer previously treated with anthracycline and taxane. J Korean Med Sci 2004; 19:547-553.
18. Ghosn M, Kattan J, Farhat F, et al. Phase II trial of capecitabine and vinorelbine as first-line chemotherapy for metastatic breast cancer patients. Anticancer Res 2006; 26:2451-2456.
19. Hess D, Thurlimann B, Pagani O, et al. Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Ann Oncol 2004; 15:1760-1765.
20. Lorusso V, Crucitta E, Silvestris N, et al. A phase I study of capecitabine in combination with vinoralbine in advanced breast cancer. Clin Breast Cancer 2003; 4:138-141.
21. Welt A, von Minckwitz G, Oberhoff C, et al. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 2005; 16:64-69.
22. Gebbia V, Puozzo C. Oral versus intravenous vinorelbine: clinical safety profile. Expert Opin Drug Saf 2005; 4:915-928.
23. Depierre A, Freyer G, Jassem J, et al. Oral vinorelbine: feasibility and safety profile. Ann Oncol 2001; 12:1677-1681.
24. Freyer G, Delozier T, Lichinister M, et al. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 2003; 21:35-40.
25. Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11:1245-1252.
26. Garcia-Conde J, Lluch A, Martin M, et al. Phase II trial of weekly IV vinorelbine in first-line advanced breast cancer chemotherapy. Ann Oncol 1994; 5:854-857.
27. Romero A, Rabinovich MG, Vallejo CT, et al. Vinoralbine as first-line chemotherapy for metastatic breast carcinoma. J Clin Oncol 1994; 12:336-341.
28. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
29. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15:110-115.
30. Nolé F, Catania C, Sanna G, et al. Dose-finding and pharmacokinetic study of an all-oral combination regimen of oral vinorelbine and capecitabine for patients with metastatic breast cancer. Ann Oncol 2006; 17:322-329.
31. Nolé F, Catania C, Munzone E, et al. Capecitabine/vinorelbine: an effective and well-tolerated regimen for women with pretreated advanced-stage breast cancer. Clin Breast Cancer 2006; 6:518-524.